Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Rules and Regulations 85047 

1 21 U.S.C. 811(a). 

2See Schedules of Controlled Substances: 

Temporary Placement of Butonitazene, 

Etodesnitazene, Flunitazene, Metodesnitazene, 

Metonitazene, N-Pyrrolidino etonitazene, and 

Protonitazene in Schedule I, 87 FR 21556 (Apr. 12, 

2022). The four additional benzimidazole-opioids 

were etodesnitazene, metonitazene, N-pyrrolidino 

etonitazene, and protonitazene. DEA pursued 

separate scheduling actions for metonitazene, see 

88 FR 56466 (Aug. 18, 2023) and for etodesnitazene, 

N-pyrrolidino etonitazene, and protonitazene, see 

89 FR 25514 (Apr. 11, 2024) to remain as schedule 

I substances under the CSA in order to meet the 

United States’ obligations under the United Nations 

Single Convention on Narcotic Drugs, Mar. 30, 

1961, 18 U.S.T. 1407, 520 U.N.T.S. 151 (Single 

Convention), as amended by the 1972 Protocol. 

3See Schedules of Controlled Substances: 

Extension of Temporary Placement of Butonitazene, 

Flunitazene, and Metodesnitazene in Schedule I of 

the Controlled Substances Act, 89 FR 25517 (Apr. 

11, 2024). 

4See Schedules of Controlled Substances: 

Placement of Butonitazene, Flunitazene, and 

Metodesnitazene Substances in Schedule I, 89 FR 

25544 (Apr. 11, 2024). 

5 DEA published a final order to permanently 

place the three other benzimidazole-opioids 

(etodesnitazene, N-pyrrolidino etonitazene, and 

protonitazene) in schedule I of the CSA. See 

Schedules of Controlled Substances: Placement of 

Etodesnitazene, N-Pyrrolidino Etonitazene, and 

Protonitazene in Schedule I, 89 FR 25514 (Apr. 11, 

2024). 

(ii) Parker Meggitt Service Bulletin 

1111548–25–001–2023, Revision 002, dated 

April 1, 2024. 

(3) For Parker Meggitt material identified 

in this AD, contact Parker Meggitt Services, 

1785 Voyager Avenue, Simi Valley, CA 

93063; phone: 877–666–0712; email: 

TechSupport@meggitt.com; website: 

meggitt.com/services_and_support/ 

customer_experience/update-on-buckleassembly-service-bulletins. 

(4) You may view this material at the FAA, 

Office of the Regional Counsel, Southwest 

Region, 10101 Hillwood Parkway, Room 6N– 

321, Fort Worth, TX 76177. For information 

on the availability of this material at the 

FAA, call (817) 222–5110. 

(5) You may view this material at the 

National Archives and Records 

Administration (NARA). For information on 

the availability of this material at NARA, 

visit www.archives.gov/federal-register/cfr/ 

ibr-locations or email fr.inspection@nara.gov. 

Issued on October 21, 2024. 

Steven W. Thompson, 

Acting Deputy Director, Compliance & 

Airworthiness Division, Aircraft Certification 

Service. 

[FR Doc. 2024–24756 Filed 10–24–24; 8:45 am] 

BILLING CODE 4910–13–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–900N] 

Schedules of Controlled Substances: 

Placement of Butonitazene, 

Flunitazene, and Metodesnitazene 

Substances in Schedule I 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final rule. 

SUMMARY: The Drug Enforcement 

Administration places butonitazene, 

flunitazene, and metodesnitazene 

including their isomers, esters, ethers, 

salts and salts of isomers, esters and 

ethers in schedule I of the Controlled 

Substances Act. The regulatory controls 

and administrative, civil, and criminal 

sanctions applicable to schedule I 

controlled substances on persons who 

handle (manufacture, distribute, reverse 

distribute, import, export, engage in 

research, conduct instructional 

activities or chemical analysis with, or 

possess), or propose to handle these 

three specific controlled substances will 

continue to apply as a result of this 

action. 

DATES: Effective October 25, 2024. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Terrence L. Boos, Drug and Chemical 

Evaluation Section, Diversion Control 

Division, Drug Enforcement 

Administration; Telephone: (571) 362– 

3249. 

SUPPLEMENTARY INFORMATION: In this 

final rule, the Drug Enforcement 

Administration (DEA) permanently 

schedules the following three controlled 

substances in schedule I of the 

Controlled Substances Act (CSA), 

including their isomers, esters, ethers, 

salts, and salts of isomers, esters, and 

ethers whenever the existence of such 

isomers, esters, ethers, and salts is 

possible within the specific chemical 

designation: 

• Butonitazene (2-(2-(4- 

butoxybenzyl)-5-nitro-1H-benzimidazol1-yl)-N,N-diethylethan-1-amine), 

• Flunitazene (N,N-diethyl-2-(2-(4- 

fluorobenzyl)-5-nitro-1H-benzimidazol1-yl)ethan-1-amine), 

• Metodesnitazene (N,N-diethyl-2-(2- 

(4-methoxybenzyl)-1H-benzimidazol-1- 

yl)ethan-1-amine). 

Legal Authority 

The CSA provides that proceedings 

for the issuance, amendment, or repeal 

of the scheduling of any drug or other 

substance may be initiated by the 

Attorney General (delegated to the 

Administrator of DEA pursuant to 28 

CFR 0.100) on his own motion, at the 

request of the Secretary of Health and 

Human Services (HHS), or on the 

petition of any interested party.1 This 

action is supported, inter alia, by a 

recommendation from the Assistant 

Secretary for Health of HHS (Assistant 

Secretary for HHS or Assistant 

Secretary) and an evaluation of all other 

relevant data by DEA. This action 

continues the imposition of the 

regulatory controls and administrative, 

civil, and criminal sanctions of schedule 

I controlled substances on any person 

who handles (manufactures, distributes, 

imports, exports, engages in research, or 

conducts instructional activities or 

chemical analysis with, or possesses) or 

proposes to handle butonitazene, 

flunitazene, and metodesnitazene. 

Background 

On April 12, 2022, pursuant to 21 

U.S.C. 811(h)(1), DEA published an 

order in the Federal Register 

temporarily placing butonitazene, 

flunitazene, metodesnitazene, and four 

additional benzimidazole-opioids in 

schedule I of the Controlled Substances 

Act (CSA) based upon a finding that 

these substances pose an imminent 

hazard to the public safety.2 That 

temporary order was effective upon the 

date of publication. Under 21 U.S.C. 

811(h)(2), the temporary scheduling of a 

substance expires at the end of two 

years from the date of issuance of the 

scheduling order, except that DEA may 

extend temporary scheduling of that 

substance for up to one year during the 

pendency of permanent scheduling 

proceedings under 21 U.S.C. 811(a)(1) 

with respect to the substance. Pursuant 

to 21 U.S.C. 811(h)(2), the temporary 

scheduling of butonitazene, flunitazene, 

and metodesnitazene was set to expire 

on April 12, 2024. However, on April 

11, 2024, the DEA Administrator 

extended the temporary order in a 

separate action.3 On the same day, the 

Administrator, on her own motion 

pursuant to 21 U.S.C. 811(a), initiated 

scheduling proceedings and published a 

notice of proposed rulemaking (NPRM) 

to permanently control butonitazene, 

flunitazene, and metodesnitazene in 

schedule I of the CSA.4 Specifically, 

DEA proposed to add these substances 

to the opiates list under 21 CFR 

1308.11(b). 

DEA and HHS Eight Factor Analyses 

On November 15, 2023, the Assistant 

Secretary submitted HHS’s scientific 

and medical evaluation and scheduling 

recommendation for butonitazene, 

flunitazene, metodesnitazene, and three 

other benzimidazole-opioids and their 

salts to the Administrator,5 which 

recommended placing butonitazene, 

flunitazene, and metodesnitazene and 

their salts in schedule I of the CSA. In 

accordance with 21 U.S.C. 811(c), upon 

receipt of the scientific and medical 

evaluation and scheduling 


ddrumheller on DSK120RN23PROD with RULES1
85048 Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Rules and Regulations 

6See Schedules of Controlled Substances: 

Placement of Butonitazene, Flunitazene, and 

Metodesnitazene Substances in Schedule I, 89 FR 

25544 (Apr. 11, 2024). 

7 21 U.S.C. 812(b). 

8To place a drug or other substance in schedule 

I under the CSA, DEA must consider whether the 

substance has a currently accepted medical use in 

treatment in the United States. 21 U.S.C. 

812(b)(1)(B). There is no evidence suggesting that 

butonitazene, flunitazene, and metodesnitazene 

have a currently accepted medical use in treatment 

in the United States. To determine whether a drug 

or other substance has a currently accepted medical 

use, DEA has traditionally applied a five-part test 

to a drug or substance that has not been approved 

by the FDA: i. The drug’s chemistry must be known 

and reproducible; ii. there must be adequate safety 

studies; iii. there must be adequate and wellcontrolled studies proving efficacy; iv. the drug 

must be accepted by qualified experts; and v. the 

scientific evidence must be widely available. See 

Marijuana Scheduling Petition; Denial of Petition; 

Remand, 57 FR 10499 (Mar. 26, 1992), pet. for rev. 

denied, Alliance for Cannabis Therapeutics v. Drug 

Enforcement Admin., 15 F.3d 1131, 1135 (D.C. Cir. 

1994). DEA and HHS applied the traditional fivepart test for currently accepted medical use in this 

matter. In a recent published letter in a different 

context, HHS applied an additional two-part test to 

determine currently accepted medical use for 

substances that do not satisfy the five-part test: (1) 

whether there exists widespread, current 

experience with medical use of the substance by 

licensed health care practitioners operating in 

accordance with implemented jurisdictionauthorized programs, where medical use is 

recognized by entities that regulate the practice of 

medicine, and, if so, (2) whether there exists some 

credible scientific support for at least one of the 

medical conditions for which part (1) is satisfied. 

On April 11, 2024, the Department of Justice’s 

Office of Legal Counsel (OLC) issued an opinion, 

which, among other things, concluded that HHS’s 

two-part test would be sufficient to establish that a 

drug has a currently accepted medical use. Office 

of Legal Counsel, Memorandum for Merrick B. 

Garland Attorney General Re: Questions Related to 

the Potential Rescheduling of Marijuana at 3 (April 

11, 2024). For purposes of this final rule, there is 

no evidence that health care providers have 

widespread experience with medical use of 

butonitazene, flunitazene, and metodesnitazene, or 

that the use of butonitazene, flunitazene, and 

metodesnitazene are recognized by entities that 

regulate the practice of medicine under either the 

traditional five-part test or the two-part test. 

9 21 U.S.C. 812(b)(1). 

recommendation from HHS, DEA 

reviewed the documents and all other 

relevant data, and conducted its own 

eight-factor analysis of the abuse 

potential of these three substances. 

Please note that both the DEA and HHS 

eight-factor analyses are available in 

their entirety under the tab ‘‘Supporting 

Documents’’ of the public docket for 

this action at http://www.regulations.

gov under Docket Number ‘‘DEA– 

900N.’’ 

Determination To Permanently 

Schedule Butonitazene, Flunitazene, 

and Metodesnitazene 

After review of the available data 

including the scientific and medical 

evaluation and the scheduling 

recommendation from HHS, DEA 

published an NPRM in the Federal 

Register on April 11, 2024, which 

proposed the placement of 

butonitazene, flunitazene, and 

metodesnitazene in schedule I of the 

CSA.6 The NPRM provided an 

opportunity for interested persons to file 

a request for a hearing in accordance 

with DEA regulations on or before May 

13, 2024. DEA received no hearing 

requests. The NPRM also provided an 

opportunity for interested persons to 

submit comments on the proposed rule 

on or before May 13, 2024. 

Comments Received 

DEA received two comments on the 

proposed rule to control butonitazene, 

flunitazene, and metodesnitazene in 

schedule I of the CSA. One commenter 

provided support for the rule. This 

commenter noted that permanent 

placement of these substances would be 

beneficial to the community safety. DEA 

appreciates the support for this 

rulemaking. The second commenter 

commended the proposed rule but 

noted that a class control action for the 

nitazene drug class would be more 

appropriate as opposed to individually 

scheduling substances in the 

benzimidazole-opioid drug class. DEA 

appreciates this comment as a potential 

alternative for consideration. However, 

due to the current threat of these 

specific substances, DEA will continue 

with solely scheduling these three 

substances. 

Scheduling Conclusion 

After consideration of the relevant 

matters presented through public 

comments, the scientific and medical 

evaluation and accompanying 

scheduling recommendation of HHS, 

and DEA’s own eight-factor analysis, 

DEA finds that these facts and all 

relevant data constitute substantial 

evidence of potential for abuse of 

butonitazene, flunitazene, and 

metodesnitazene. DEA is therefore 

permanently scheduling these three 

benzimidazole-opioids as schedule I 

controlled substances under the CSA. 

Determination of Appropriate Schedule 

The CSA establishes five schedules of 

controlled substances known as 

schedules I, II, III, IV, and V. The CSA 

also outlines the findings required to 

place a drug or other substance in any 

particular schedule.7 After 

consideration of the analysis and 

recommendation of the Assistant 

Secretary for HHS and review of all 

other available data, the Administrator 

of DEA, pursuant to 21 U.S.C. 811(a) 

and 21 U.S.C. 812(b)(1), finds that: 

(1) Butonitazene, flunitazene, and 

metodesnitazene have a high potential 

for abuse. Butonitazene, flunitazene, 

and metodesnitazene, similar to 

etonitazene and fentanyl, are mu-opioid 

receptor agonists. These three 

benzimidazole-opioids have analgesic 

effects, and these effects are mediated 

by mu-opioid receptor agonism. HHS 

states that substances that produce muopioid receptor agonist effects in the 

central nervous system are considered 

as having a high potential for abuse (e.g. 

morphine and fentanyl). Data obtained 

from drug discrimination studies 

indicate that butonitazene, flunitazene, 

and metodesnitazene fully substituted 

for the discriminative stimulus effects of 

morphine. 

(2) Butonitazene, flunitazene, and 

metodesnitazene have no currently 

accepted medical use in the United 

States. There are no FDA-approved drug 

products for butonitazene, flunitazene, 

and metodesnitazene in the United 

States. There are no known therapeutic 

applications for these benzimidazoleopioids, and DEA is not aware of any 

currently accepted medical uses for 

these substances in the United States.8

(3) There is a lack of accepted safety 

for use of butonitazene, flunitazene, and 

metodesnitazene under medical 

supervision. Because these substances 

have no FDA-approved medical use and 

have not been investigated as new 

drugs, their safety for use under medical 

supervision is not determined. 

Based on these findings, the 

Administrator of DEA concludes that 

butonitazene, flunitazene, and 

metodesnitazene, including their 

isomers, esters, ethers, salts, and salts of 

isomers, esters, and ethers whenever the 

existence of such isomers, esters, ethers, 

and salts is possible within the specific 

chemical designation, warrant 

continued control in schedule I of the 

CSA.9

Requirements for Handling 

Butonitazene, Flunitazene, and 

Metodesnitazene 

As discussed above, these three 

substances are currently subject to a 

temporary scheduling order, which 

added them to schedule I. Butonitazene, 

flunitazene, and metodesnitazene will 

continue to be subject to the CSA’s 

schedule I regulatory controls and 

administrative, civil, and criminal 

sanctions applicable to the manufacture, 

distribution, reverse distribution, 

dispensing, importation, exportation, 

engagement in research, and conduct of 

instructional activities or chemical 

analysis with, and possession of 

schedule I substances, including the 

following: 


ddrumheller on DSK120RN23PROD with RULES1
Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Rules and Regulations 85049 

1. Registration. Any person who 

handles (manufactures, distributes, 

reverse distributes, dispenses, imports, 

exports, engages in research, or 

conducts instructional activities or 

chemical analysis with, or possesses) or 

who desires to handle butonitazene, 

flunitazene, and metodesnitazene must 

be registered with DEA to conduct such 

activities pursuant to 21 U.S.C. 822, 

823, 957, and 958, and in accordance 

with 21 CFR parts 1301 and 1312. Retail 

sales of schedule I controlled substances 

to the general public are not allowed 

under the CSA. Possession of any 

quantity of these substances in a manner 

not authorized by the CSA is unlawful 

and those in possession of any quantity 

of these substances may be subject to 

prosecution pursuant to the CSA. 

2. Disposal of stocks. Butonitazene, 

flunitazene, and metodesnitazene must 

be disposed of in accordance with 21 

CFR part 1317, in addition to all other 

applicable federal, state, local, and tribal 

laws. 

3. Security. Butonitazene, flunitazene, 

and metodesnitazene are subject to 

schedule I security requirements and 

must be handled and stored pursuant to 

21 U.S.C. 821, 823, and 871(b), and in 

accordance with 21 CFR 1301.71– 

1301.76. Non-practitioners handling 

these three substances also must comply 

with the screening requirements of 21 

CFR 1301.90–1301.93. 

4. Labeling and Packaging. All labels 

and labeling for commercial containers 

of butonitazene, flunitazene, and 

metodesnitazene must comply with 21 

U.S.C. 825 and be in accordance with 21 

CFR part 1302. 

5. Quota. Only registered 

manufacturers are permitted to 

manufacture butonitazene, flunitazene, 

and metodesnitazene in accordance 

with a quota assigned pursuant to 21 

U.S.C. 826, and in accordance with 21 

CFR part 1303. 

6. Inventory. Any person registered 

with DEA to handle butonitazene, 

flunitazene, and metodesnitazene must 

have an initial inventory of all stocks of 

controlled substances (including these 

substances) on hand on the date the 

registrant first engages in the handling 

of controlled substances pursuant to 21 

U.S.C. 827 and 958, and in accordance 

with 21 CFR 1304.03, 1304.04, and 

1304.11. 

After the initial inventory, every DEA 

registrant must take a new inventory of 

all stocks of controlled substances 

(including butonitazene, flunitazene, 

and metodesnitazene) on hand every 

two years pursuant to 21 U.S.C. 827 and 

958, and in accordance with 21 CFR 

1304.03, 1304.04, and 1304.11. 

7. Records and Reports. Every DEA 

registrant must maintain records and 

submit reports with respect to 

butonitazene, flunitazene, and 

metodesnitazene, pursuant to 21 U.S.C. 

827, 832(a), and 958(e), and in 

accordance with 21 CFR 1301.74(b) and 

(c) and 1301.76(b) and parts 1304, 1312, 

and 1317. Manufacturers and 

distributors would be required to submit 

reports regarding butonitazene, 

flunitazene, and metodesnitazene to the 

Automation of Reports and 

Consolidated Order System pursuant to 

21 U.S.C. 827, and in accordance with 

21 CFR parts 1304 and 1312. 

8. Order Forms. Every DEA registrant 

who distributes butonitazene, 

flunitazene, and metodesnitazene must 

comply with the order form 

requirements, pursuant to 21 U.S.C. 828 

and 21 CFR part 1305. 

9. Importation and Exportation. All 

importation and exportation of 

butonitazene, flunitazene, and 

metodesnitazene must comply with 21 

U.S.C. 952, 953, 957, and 958, and be in 

accordance with 21 CFR part 1312. 

10. Liability. Any activity involving 

butonitazene, flunitazene, and 

metodesnitazene not authorized by, or 

in violation of, the CSA or its 

implementing regulations is unlawful, 

and may subject the person to 

administrative, civil, and/or criminal 

sanctions. 

Regulatory Analyses 

Executive Orders 12866 (Regulatory 

Planning and Review), 13563 

(Improving Regulation and Regulatory 

Review), and 14094 (Modernizing 

Regulatory Review) 

In accordance with 21 U.S.C. 811(a), 

this final scheduling action is subject to 

formal rulemaking procedures done ‘‘on 

the record after opportunity for a 

hearing,’’ which are conducted pursuant 

to the provisions of 5 U.S.C. 556 and 

557. The CSA sets forth the criteria for 

scheduling a drug or other substance. 

Such actions are exempt from review by 

the Office of Management and Budget 

(OMB) pursuant to section 3(d)(1) of 

Executive Order (E.O.) 12866 and the 

principles reaffirmed in E.O. 13563. 

E.O. 14094 modernizes the regulatory 

review process to advance policies that 

promote the public interest and address 

national priorities. 

Executive Order 12988, Civil Justice 

Reform 

This regulation meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of E.O. 12988 to eliminate 

drafting errors and ambiguity, minimize 

litigation, provide a clear legal standard 

for affected conduct, and promote 

simplification and burden reduction. 

Executive Order 13132, Federalism 

This rulemaking does not have 

federalism implications warranting the 

application of E.O. 13132. The rule does 

not have substantial direct effects on the 

states, on the relationship between the 

national government and the States, or 

the distribution of power and 

responsibilities among the various 

levels of government. 

Executive Order 13175, Consultation 

and Coordination With Indian Tribal 

Governments 

This rule does not have tribal 

implications warranting the application 

of E.O. 13175. It does not have 

substantial direct effects on one or more 

Indian tribes, on the relationship 

between the Federal government and 

Indian tribes, or on the distribution of 

power and responsibilities between the 

Federal government and Indian tribes. 

Regulatory Flexibility Act 

The Administrator, in accordance 

with the Regulatory Flexibility Act, 5 

U.S.C. 601–612, has reviewed this rule 

and, by approving it, certifies that it will 

not have a significant economic impact 

on a substantial number of small 

entities. 

On April 12, 2022, DEA published an 

order to temporarily place seven 

benzimidazole-opioids in schedule I of 

the CSA pursuant to the temporary 

scheduling provisions of 21 U.S.C. 

811(h). DEA estimates that all entities 

handling or planning to handle 

butonitazene, flunitazene, and 

metodesnitazene have already 

established and implemented systems 

and processes required to handle these 

substances. 

There are currently 45 registrations 

authorized to specifically handle 

butonitazene, flunitazene, or 

metodesnitazene, as well as 1,239 

registered analytical labs and 861 

researchers that are authorized to 

handle schedule I controlled substances 

generally. These 45 registrations 

represent 31 entities. A review of the 45 

registrations indicates that all entities 

that currently handle butonitazene, 

flunitazene, and metodesnitazene also 

handle other schedule I controlled 

substances and have established and 

implemented (or maintained) systems 

and processes required to handle these 

substances. Therefore, DEA anticipates 

this final rule will impose minimal or 

no economic impact on any affected 

entities; and thus, will not have a 

significant economic impact on any 

affected small entity. Therefore, DEA 


ddrumheller on DSK120RN23PROD with RULES1
85050 Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Rules and Regulations 

10 44 U.S.C. 3501–3521. 

has concluded that this rule will not 

have a significant economic impact on 

a substantial number of small entities. 

Unfunded Mandates Reform Act of 1995 

In accordance with the Unfunded 

Mandates Reform Act of 1995 (UMRA), 

2 U.S.C. 1501 et seq., DEA has 

determined and certifies that this action 

would not result in any Federal 

mandate that may result ‘‘in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $100,000,000 or more 

(adjusted annually for inflation) in any 

1 year . . . .’’ Therefore, neither a Small 

Government Agency Plan nor any other 

action is required under the UMRA. 

Paperwork Reduction Act of 1995 

This rule would not impose a new 

collection or modify an existing 

collection of information under the 

Paperwork Reduction Act of 1995.10

Also, this rule would not impose new or 

modify existing recordkeeping or 

reporting requirements on state or local 

governments, individuals, businesses, or 

organizations. However, this rule would 

require compliance with the following 

existing OMB collections: 1117–0003, 

1117–0004, 1117–0006, 1117–0008, 

1117–0009, 1117–0010, 1117–0012, 

1117–0014, 1117–0021, 1117–0023, 

1117–0029, and 1117–0056. An agency 

may not conduct or sponsor, and a 

person is not required to respond to, a 

collection of information unless it 

displays a currently valid OMB control 

number. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, DEA 

amends 21 CFR part 1308 as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b), unless otherwise noted. 

■ 2. In § 1308.11: 

■ a. Redesignate paragraphs (b)(62) 

through (106) as (b)(65) through (109) 

■ b. Redesignate paragraphs (b)(44) 

through (61) as (b)(46) through (63); 

■ c. Redesignate paragraphs (b)(24) 

through (43) as (b)(25) through (44); 

■ d. Add new paragraphs (b)(24), 

(b)(45), and (b)(64); and 

■ e. Remove and reserve paragraphs 

(h)(50), (52), and (53). 

The additions to read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(b) * * * 

*******

(24) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) ................................................. 9751 

*******

(45) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) ..................................................... 9756 

*******

(64) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) ................................................... 9764 

* * * * * 

Signing Authority 

This document of the Drug 

Enforcement Administration was signed 

on October 15, 2024, by Administrator 

Anne Milgram. That document with the 

original signature and date is 

maintained by DEA. For administrative 

purposes only, and in compliance with 

requirements of the Office of the Federal 

Register, the undersigned DEA Federal 

Register Liaison Officer has been 

authorized to sign and submit the 

document in electronic format for 

publication, as an official document of 

DEA. This administrative process in no 

way alters the legal effect of this 

document upon publication in the 

Federal Register. 

Heather Achbach, 

Federal Register Liaison Officer, Drug 

Enforcement Administration. 

[FR Doc. 2024–24635 Filed 10–24–24; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF THE INTERIOR 

Bureau of Safety and Environmental 

Enforcement 

30 CFR Part 250 

[Docket ID: BSEE–2021–0003; 

EEEE500000245E1700D2 

ET1SF0000.EAQ000] 

RIN 1014–AA49 

Oil and Gas and Sulfur Operations in 

the Outer Continental Shelf—High 

Pressure High Temperature Updates; 

Correction 

AGENCY: Bureau of Safety and 

Environmental Enforcement (BSEE), 

Interior. 

ACTION: Final rule; correction. 

SUMMARY: BSEE is correcting a final rule 

that appeared in the Federal Register on 

August 30, 2024. BSEE is publishing a 

correction to fix an erroneous statement 

in the preamble of the final rule. BSEE 

inadvertently stated it did not receive 

public comments to an identified 

section of the rule. However, BSEE had 

received a comment associated with that 

section of the rule. BSEE evaluated and 

addressed that comment in other 

discussions in the preamble of the final 

rule. 

DATES: Effective October 25, 2024. 

FOR FURTHER INFORMATION CONTACT: Kirk 

Malstrom, Regulations and Standards 

Branch, (202) 258–1518, or by email: 

regs@bsee.gov. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

2024–18598 appearing on page 71088 in 

the Federal Register of Friday, August 

30, 2024, the following corrections to 

the preamble are made: 

1. Under the heading ‘‘How must 

barrier systems be used (§ 250.207)’’, 

which begins near the bottom of the 

third column on page 71087, the text 

under the subheading ‘‘Summary of 

Final Rule Revisions’’, which begins 

near the top of the first column on page 

71088, is corrected to read: 

BSEE received and considered a 

comment regarding proposed § 250.207 

and includes the proposed language in 

the final rule without change. 

Summary of Comment: A commenter 

expressed concerns with the 

applicability of this section to existing 

blowout preventer barrier system 

requirements and asked if new and 


ddrumheller on DSK120RN23PROD with RULES1